Combining MBDA score and ACPA status may allow risk stratification for successful DMARD tapering and cost-effective use of biologic DMARDs.

“Our present study shows that tapering or stopping DMARD achieves savings of direct healthcare costs, if the likelihood for relapse is low and the patients can permanently stay on a tapered DMARD regimen or could even stop treatment.”

Hagen M, et al. Cost-effective tapering algorithm in patients with rheumatoid arthritis: combination of multibiomarker disease activity score and autoantibody status. J Rheumatol. 2019; 46(5):460-466.

Learn More View Article

Vectra test changes treatment decisions, and may improve functional status and reduce costs.

“Over the 10 year time horizon, quality-adjusted life years increased by 0.08 years and costs decreased by US$457 (cost savings in disability-related medical costs, US$659; in productivity costs, US$2137).”

Michaud K, et al. Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015 Sep; 54(9): 1640–9.

Learn More View Article